Background
==========

Lung transplantation (LTx) is an effective treatment for advanced lung disease, which improves patients' quality of life and extends their life expectancy \[[@b1-anntransplant-24-647]\]. However, a profound shortage of donors and underutilization of donor lungs remains a significant challenge in performing LTx \[[@b2-anntransplant-24-647],[@b3-anntransplant-24-647]\]. In addition to the use of marginal donors and living donors to expand the donor organ pool, *ex vivo* lung perfusion (EVLP) technology can reduce receptor waiting list mortality by improving donor lung utilization and increasing LTx activity \[[@b4-anntransplant-24-647],[@b5-anntransplant-24-647]\].

EVLP is a relatively new technology for the procurement of donor lungs which was initially developed as a method for assessing graft quality and improving cardiac death (DCD) donor lung function \[[@b6-anntransplant-24-647],[@b7-anntransplant-24-647]\]. The first successful use of EVLP to assess and recondition LTx in donor lungs was reported by Steen et al. in 2001, which was the starting point for the "Lund protocol" \[[@b7-anntransplant-24-647]\]. In 2008, Cypel et al. \[[@b8-anntransplant-24-647]\] in Toronto reported the use of a novel strategy to expand the EVLP assessment of lung function, which laid the foundation for the "Toronto protocol". In 2012, Warnecke et al. in Hanover reported the first-in-human experience using the portable Organ Care System (OCS) lung device for concomitant preservation, assessment, and transport of donor lungs, which was known as "OCS protocol" \[[@b9-anntransplant-24-647]\]. EVLP has evolved to demonstrate that marginal donor lungs could be assessed and treated to achieve similar early outcomes as the standard criteria donor lungs \[[@b5-anntransplant-24-647]\]. In addition, due to the process of EVLP not being regarded as "ischemic time", EVLP might play an essential role in expanding the procurement time and contributing to the long-distance transportation, especially using the portable OCS technique \[[@b9-anntransplant-24-647]\]. EVLP technology has attracted more and more attention from transplant centers around the world, but there are still serious concerns about the poor results after transplantation. Although several comparative analyses of clinical outcome between EVLP and traditional cold storage have been reported and some multicenter randomized control clinical trials (RCTs) are being conducted, there are still a lot of uncertainty about EVLP clinical application. Thus, this meta-analysis was performed to determine the short- mid- to long-term results of EVLP compared with that of standard cold storage.

Material and Methods
====================

Literature search strategy
--------------------------

The meta-analysis was performed according to the recommendations of the Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) statement \[[@b10-anntransplant-24-647]\]. The electronic databases, including PubMed, PMC, EMBASE, and Ovid, were comprehensively searched for relevant articles published until March 1, 2019. Search terms included the following: "EVLP or *ex vivo* lung perfusion" and "lung transplantation". All references reported in the identified articles were also scanned to identify potentially relevant reports.

Criteria for inclusion and exclusion
------------------------------------

The studies included in this meta-analysis need to meet the following criteria: 1) RCTs or cohort studies studying lung transplantation; and 2) studies comparatively analyze the post-transplantation results between EVLP technique and traditional cold storage. The following studies were excluded: 1) articles about animals; 2) single-arm analysis about EVLP technique; and 3) review articles without original data. For duplicate articles reporting the same case population, only the most complete or up-to-date one was included. Two reviewers independently selected eligible studies. Disagreements were settled by discussion.

Data extraction and quality assessment
--------------------------------------

The following data was collected independently by 2 reviewers using a predesigned form, comprising first author, publication year, study period, country, study design, sample size (donors and recipients), age (donors and recipients), gender (donors and recipients), type of donor, time in ventilation (donors and recipients), chest x-ray abnormalities, PaO~2~/FiO~2~ 100% (P/F, donors and recipients), indication for LTx, type of LTx, lung allocation score (LAS), extracorporeal membrane oxygenation (ECMO) bridge to LTx, intraoperative extracorporeal circulation (ECC)/ECMO, reason for EVLP, technological type of EVLP, EVLP solution, EVLP duration, the number of accepted donor after EVLP, severe primary graft dysfunction (PGD) after LTx, post-LTx ECMO, residence time in the intensive care unit (ICU), total length of hospital stay, FEV1 of the predicted value (FEV1%), FVC of the predicted value (FVC%), follow-up time and survival data after LTx. The hazard ratio (HR) and 95% confidence intervals (CI) of the EVLP group compared to the traditional cold storage group for OS were primarily collected. If the HR and 95% CI were not explicitly provided, we used Tierney's methods to extract survival data from the original study data or Kaplan-Meier curve \[[@b11-anntransplant-24-647]\]. If the aforementioned items were not reported in the original study, the items were labeled as "not available (NA)". Inconsistencies in the process were solved by consultations.

The quality of the included cohort studies was independently assessed by 2 reviewers according to the Newcastle-Ottawa Scale (NOS) \[[@b12-anntransplant-24-647]\]. The NOS evaluated a study with the score ranged from 0 to 9. A study with a score of 6 or high was considered as a high-quality one. The quality of RCT reports was measured by the Jadad scale \[[@b13-anntransplant-24-647]\]. The Jadad scale evaluated a study from 3 perspectives, including randomization, blinding, and withdraw, with scores ranging from 0 to 5. A study achieving a score of 3 or more was identified as a high-quality one.

Statistical analysis
--------------------

Interest results included improvement of P/F ratio in donor lung after EVLP, total cold ischemic time (CIT) and preservation time in donor lung, P/F ratio after LTx, extubation time, severe incidence of PGD after LTx, requirement of ECMO, residence time in the intensive care unit (ICU), total length of hospital stay, FEV1%, FVC%, survival rate at 30 days, 90 days and 1-year after LTx, and accumulative survival. The HR and 95% CI were used as an effect size (ES) to assess the impact of EVLP on accumulative survival outcomes. Relative risk (RR) with its 95% CI and Mantel-Haenszel model were used to measure the effect of EVLP on categorical variables. For continuous outcomes, weighted mean difference (WMD) was used as the ES to assess the difference between the EVLP group and the traditional group. Heterogeneity across the studies was tested using I-squared statistics \[[@b14-anntransplant-24-647]\]. I^2^≤50% indicated no or moderate heterogeneity, in which case a fixed-effect model was used. I^2^\>50% showed statistically significant heterogeneity, in which case a random-effect model is chosen. To explore the difference among Lund, Toronto, and OCS protocols, subgroup analyses based on different protocols were adopted. Sensitivity analysis by omitting a single study to confirm the robustness of the combined results. By convention, an observed ES\>1 implied a more unsatisfactory outcome for the EVLP group compared with the traditional cold storage group. Assessment of potential publication bias was conducted through Begg's funnel plot and Egger's test. Data are presented as mean±standard deviations (SD), median (ranges), or median (inter-quartile range, IQR). Stata software version 12.0 (Stata Corporation, TX, USA) was used in the meta-analysis. All the tests were 2-sided, and *P*\<0.05 was considered statistically significant.

Results
=======

Study selection and characteristics
-----------------------------------

The results of articles selection are shown in [Figure 1](#f1-anntransplant-24-647){ref-type="fig"}. A total of 789 articles were identified initially using the search strategy described. We excluded 738 articles because they were duplicate documents, review articles, or irrelevant studies. Afterward, 51 articles were read in full text. Finally, 20 articles were considered suitable for inclusion in the meta-analysis. Among the eligible study, the NOVEL trial \[[@b15-anntransplant-24-647]\] is expected to end in 2020, and its 1-year results have been reported in summary form. Considering that the NOVEL trial is an RCT study and can provide some available information, such as necessary patient information, donor lung conversion rate, 30-day survival, and 1-year survival, it was included in our study.

[Table 1](#t1-anntransplant-24-647){ref-type="table"} listed the main features of the 20 eligible articles \[[@b4-anntransplant-24-647],[@b15-anntransplant-24-647]--[@b33-anntransplant-24-647]\] Three RCTs, 3 prospective cohort studies, and 14 retrospective cohort studies were included, and the publication year ranged from 2011 to 2018. The study included a total of 2574 donors and 2567 recipients. [Table 1](#t1-anntransplant-24-647){ref-type="table"} and [Figure 2](#f2-anntransplant-24-647){ref-type="fig"} show the features of the donor, and [Table 2](#t2-anntransplant-24-647){ref-type="table"} and [Figure 3](#f3-anntransplant-24-647){ref-type="fig"} show the characteristics of the recipient. There was no significant difference in the donors' age ([Figure 2A](#f2-anntransplant-24-647){ref-type="fig"}), gender ([Figure 2B](#f2-anntransplant-24-647){ref-type="fig"}), donor type ([Figure 2C](#f2-anntransplant-24-647){ref-type="fig"}), and mechanical ventilation time ([Figure 2D](#f2-anntransplant-24-647){ref-type="fig"}) between the EVLP group and the traditional cold storage group. However, compared with the non-EVLP group, the EVLP group donors had more chest X-ray abnormalities (RR 1.39, 95% CI 1.03--1.87, *P*\<0.05, [Figure 2E](#f2-anntransplant-24-647){ref-type="fig"}) and more inferior P/F ratio (WMD −106.06, 95% CI −150.78--61.33 mmHg, *P*\<0.001, [Figure 2F](#f2-anntransplant-24-647){ref-type="fig"}). There was also no significant difference for recipients' age ([Figure 3A](#f3-anntransplant-24-647){ref-type="fig"}), LAS ([Figure 3C](#f3-anntransplant-24-647){ref-type="fig"}), mechanical ventilation pre-LTx ([Figure 3D](#f3-anntransplant-24-647){ref-type="fig"}), ECMO bridging to LTx ([Figure 3E](#f3-anntransplant-24-647){ref-type="fig"}), type of LTx ([Figure 3F](#f3-anntransplant-24-647){ref-type="fig"}), or total CIT ([Figure 4A](#f4-anntransplant-24-647){ref-type="fig"}). Still the EVLP group had more female patients ([Figure 3B](#f3-anntransplant-24-647){ref-type="fig"}) and showed more intraoperative ECC/ECMO needs (RR 1.34, 95% CI 1.01--1.78, *P*\<0.05, [Figure 3G](#f3-anntransplant-24-647){ref-type="fig"}) and longer preservation time (WMD 379.54, 95% CI 271.16--487.91 minute, *P*\<0.001, [Figure 4B](#f4-anntransplant-24-647){ref-type="fig"}) compared with the traditional cold storage group. In the subgroup analysis based on different protocols, the OCS subgroup exhibited equivalence between the 2 groups but the shorter total CIT in the OCS-EVLP group ([Figure 4A](#f4-anntransplant-24-647){ref-type="fig"}).

The efficacy of EVLP in improving donor lungs
---------------------------------------------

The parameters of EVLP and its role in conversing marginal donor lungs are summarized in [Table 3](#t3-anntransplant-24-647){ref-type="table"} and [Figure 5](#f5-anntransplant-24-647){ref-type="fig"}. Compared with the P/F pre-EVLP, the P/F after EVLP was significantly improved (WMD 184.38, 95% CI 130.17--238.59 mmHg, *P*\<0.001, [Figure 5](#f5-anntransplant-24-647){ref-type="fig"}). However, the OCS subgroup did not show significant improvement in P/F ([Figure 5](#f5-anntransplant-24-647){ref-type="fig"}), which might be because 1 study in the OCS subgroup involved only standard criteria donors \[[@b16-anntransplant-24-647]\]. The conversion rate of donor lungs by EVLP ranged from 34% to 100%. Among those included studies, a total of 1985 cases received traditional cold storage LTx, and 582 cases received EVLP LTx, so it can be said that EVLP made a 29.3% contribution to the LTx activity.

The effect of EVLP on outcomes of recipients
--------------------------------------------

As shown in [Figures 6](#f6-anntransplant-24-647){ref-type="fig"} and [7](#f7-anntransplant-24-647){ref-type="fig"}, there was no significant difference about P/F after LTx ([Figure 6A](#f6-anntransplant-24-647){ref-type="fig"}), time to extubation ([Figure 6B](#f6-anntransplant-24-647){ref-type="fig"}), postoperative ECMO requirement ([Figure 6D](#f6-anntransplant-24-647){ref-type="fig"}), length of hospital stays ([Figure 6F](#f6-anntransplant-24-647){ref-type="fig"}), FEV1% ([Figure 6G](#f6-anntransplant-24-647){ref-type="fig"}), FVC% ([Figure 6H](#f6-anntransplant-24-647){ref-type="fig"}), survival rate at 30 days ([Figure 7A](#f7-anntransplant-24-647){ref-type="fig"}), 90 days ([Figure 7B](#f7-anntransplant-24-647){ref-type="fig"}) and 1 year ([Figure 7C](#f7-anntransplant-24-647){ref-type="fig"}) after LTx, and accumulative survival after LTx ([Figure 7D](#f7-anntransplant-24-647){ref-type="fig"}) between the EVLP group and the non-EVLP group. However, compared with the non-EVLP group, the EVLP group showed a lower incidence of PGD 3 ([Figure 6C](#f6-anntransplant-24-647){ref-type="fig"}) after LTx, but the longer length of ICU stays ([Figure 6E](#f6-anntransplant-24-647){ref-type="fig"}).

Sensitivity analyses and publication bias
-----------------------------------------

The corresponding pooled ESs did not alter significantly during the sensitivity analysis process, suggesting robustness of the results. Publication bias was tested using Begg's funnel plot and Egger's test. No significant publication bias was observed in either the visualization of the funnel plot ([Figure 8](#f8-anntransplant-24-647){ref-type="fig"}, *P*=0.381) or Egger's test (*P*=0.272).

Discussion
==========

EVLP as a new technique not only could preserve donor lungs but also could be used to assess and recondition/improve the borderline lungs, so it has a great potential to replace the standard cold storage in the procurement of donor lungs. However, synthetic comparative analysis of EVLP technique and standard cold storage in LTx is limited, especially for low-quality donor lungs. This present meta-analysis systematically evaluated the impact of EVLP on LTx outcomes compared with standard cold storage. In the 2 RCTs included, donors in the EVLP group were standard criteria donors \[[@b16-anntransplant-24-647],[@b17-anntransplant-24-647]\]. Still in other studies, donors in the EVLP group were expanded criteria donors, marginal donors, or initially rejected donors. Combined analyses about donor features showed that the EVLP group had more chest x-ray abnormalities and a poorer P/F ratio than the traditional cold storage group. After the process of EVLP, the poor P/F ratio in the EVLP group was significantly improved with the conversion rate of marginal/rejected donor lungs ranging from 34% to 100%, which promoted the LTx growth by about 29.3%. Luc et al. \[[@b18-anntransplant-24-647]\] and Machuca et al. \[[@b19-anntransplant-24-647]\] only involved DCD donors and reported the comparison between DCD lungs that underwent EVLP and those transplanted without the use of EVLP, which indicated that EVLP could improve the utilization of extended criteria DCD lungs.

The preservation time in donor lung was much longer in the EVLP group than that in the traditional cold storage group, especially in the Toronto and Lund subgroups. Although the total CIT was similar between the EVLP group and the traditional cold storage group, Toronto and Lund subgroups exhibited longer total CIT in the EVLP group, and the OCS subgroup exhibited shorter total CIT in the EVLP group. Thus, the extra part of preservation time in the EVLP group consisted primarily of the EVLP process, and a longer total CIT. The wide gap between WMD of preservation time (379.54 minutes) and WMD of total CIT (73.28 minutes) could be more approximate to the duration of EVLP, which indicated that EVLP could play an essential role for the expansion of the procurement time \[[@b16-anntransplant-24-647]\]. In addition, the OCS protocol based portable EVLP device may allow a significantly shorter CIT and more extended distance transport for donor lungs \[[@b16-anntransplant-24-647]\].

The clinical-pathologic features of the recipients between the EVLP and the non-EVLP groups were equivalent, except the EVLP group had more female composition and required more intraoperative ECC/ECMO than the non-EVLP group. There were no significant differences between the 2 groups in using mechanical ventilation/ECMO support after LTx. PGD was graded based on the International Society for Heart and Lung Transplantation (ISHLT) criteria, with grade 3 representing P/F ratio \<200 within 72 hours and radiographic infiltrates \[[@b34-anntransplant-24-647],[@b35-anntransplant-24-647]\]. The EVLP recipients had less incidence of PGD3 throughout the initial 72 hours after LTx than the non-EVLP recipients. However, the length of ICU stays of the EVLP group was longer than the non-EVLP group. This may be probably because the OCS subgroup contributed less incidence of PGD3 ([Figure 6C](#f6-anntransplant-24-647){ref-type="fig"}), and the Lund subgroup donated more extended ICU stays ([Figure 6E](#f6-anntransplant-24-647){ref-type="fig"}). The peak pulmonary function (FEV1% and FVC%) after LTx, and the short-to long-term survival outcomes were all similar between the 2 groups.

Despite our efforts to conduct a comprehensive analysis, there are still some limitations that need to be recognized. First, most of the included studies in our analysis were retrospective cohort studies that provided only weaker statistical power. Second, some studies have shown a relatively small number of patients, which may affect the validity of the statistics. Third, several ESs and its 95% CI were calculated by extracting the data from Kaplan-Meier curves, which might bring statistical deviations inevitably. Finally, donor/recipient characteristics, EVLP processes, and follow-up showed significant heterogeneity. Although random-effect models, subgroup analyses, and sensitivity analyses were performed to address this heterogeneity, these results should still be interpreted with caution.

Conclusions
===========

In our study, EVLP can be used to assess and improve the quality of high-risk donor lungs to expand lung supply and improve donor lung utilization. Additionally, the application of EVLP is non-inferior to standard cold storage regarding postoperative outcomes. Considering an RCT designed for improving low-quality donor lung with EVLP might be problematic from an ethical point, this study can be a rationale for further work.
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###### 

Summary of included studies and donor characteristics.

  Author                                             Year   Period       Country                              Design               Samples size   Age (years)   Gender          Type of donor   Quality                                                        
  -------------------------------------------------- ------ ------------ ------------------------------------ -------------------- -------------- ------------- --------------- --------------- ------------ -------------- ---------------- ----------------- ---------
  Koch et al. \[[@b20-anntransplant-24-647]\]        2018   2016--2017   Germany                              Cohort               11             41            54±14           54±16           F 3, M 8     F 20, M 21     DBD 11           DBD 41            Jadad 3
  Warnecke et al. \[[@b16-anntransplant-24-647]\]    2018   2011--2014   USA, Europe, Australia, and Canada   RCT                  151            169           42.2±14.4       40.2±13.7       F 72, M 79   F 67, M 102    NA               NA                NOS 8
  Nilsson et al. \[[@b21-anntransplant-24-647]\]     2018   2011--2015   Sweden                               Prospective cohort   61             271           NA              NA              NA           NA             DBD 61           DBD 271           NOS 8
  Zhang et al. \[[@b22-anntransplant-24-647]\]       2018   2012--2016   Netherlands                          Cohort               9              18            41±12.7         52±16.3         F 5, M 4     F 9, M 9       DBD6, DCD 3      DBD 11, DCD 7     NOS 7
  Slama et al. \[[@b17-anntransplant-24-647]\]       2017   2013--2015   Austria                              RCT                  35             41            45 (18--71)     44 (19--76)     F 18, M 17   F 12, M 27     DBD 35           DBD 41            Jadad 3
  Luc et al. \[[@b18-anntransplant-24-647]\]         2017   2011--2015   Canada                               Cohort               7              4             48±11           40±20           F 4, M 3     F 1, M 3       DCD 7            DCD 4             NOS 6
  Wallinder et al. \[[@b23-anntransplant-24-647]\]   2016   2011--2013   Sweden                               Cohort               27             145           47±18           50±17           NA           NA             DBD 27           DBD 145           NOS 8
  Fisher et al. \[[@b24-anntransplant-24-647]\]      2016   2012--2014   UK (five centers)                    Cohort               18             184           50.5 (22--61)   44 (10--68)     F 8, M 10    F 96, M 86     DBD 13, DCD 5    DBD 152, DCD 31   NOS 7
  Machuca et al. \[[@b19-anntransplant-24-647]\]     2015   2007--2013   Canada                               Cohort               28             27            45±13           39±19           F 13, M 15   F 11, M 16     DCD 28           DCD 27            NOS 8
  Tikkanen et al. \[[@b25-anntransplant-24-647]\]    2015   2008--2012   Canada                               Cohort               63             340           43.1±14.9       45.8±17.6       F 31, M 32   F 180, M 160   DBD 36, DCD 27   DBD 322, DCD 18   NOS 8
  Fildes et al. \[[@b26-anntransplant-24-647]\]      2015   2012--2014   UK and Sweden                        Cohort               9              46            54±10.1         45±13.1         F 4, M 5     F 30, M 16     NA               NA                NOS 6
  Sanchez et al. \[[@b15-anntransplant-24-647]\]     2014   2011--2013   US (six centers)                     RCT (abstract)       42             42            NA              NA              NA           NA             DBD 36, DCD 6    DBD 41, DCD 1     NA
  Sage et al. \[[@b29-anntransplant-24-647]\]        2014   2011--2013   France                               Prospective cohort   31             81            48 (21--67)     51 (14--70)     NA           NA             DBD 31           DBD 81            NOS 7
  Boffini et al. \[[@b28-anntransplant-24-647]\]     2014   2011--2013   Italy                                Cohort               8              28            44.7±16.2       43.3±16.8       F 7, M 1     F 13, M 15     DBD 8            DBD 28            NOS 6
  Valenza et al. \[[@b4-anntransplant-24-647]\]      2014   2011--2013   Italy                                Cohort               7              28            54±9            40±15           NA           NA             DBD 7            DBD 28            NOS 6
  Wallinder et al. \[[@b29-anntransplant-24-647]\]   2014   2011--2013   Sweden                               Cohort               11             47            56 (19--61)     NA              NA           NA             DBD 11           DBD 47            NOS 6
  Cypel et al. \[[@b30-anntransplant-24-647]\]       2012   2008--2011   Canada                               Cohort               50             253           Median 45       Median 45       NA           NA             DBD 22, DCD 28   DBD 240, DCD 13   NOS 8
  Zych et al. \[[@b31-anntransplant-24-647]\]        2012   2009--2010   UK                                   Cohort               6              86            43.5±15.1       NA              F 2, M 4     NA             DBD 10, DCD 3    NA                NOS 6
  Aigner et al. \[[@b32-anntransplant-24-647]\]      2012   2010--2011   Austria                              Prospective cohort   9              119           48 (16--58)     NA              NA           NA             DBD 13           DBD 119           NOS 6
  Lindstedt et al. \[[@b33-anntransplant-24-647]\]   2011   2006--2007   Sweden                               Cohort               6              15            59 (34--63)     NA              F 3, M 3     NA             DBD 6            DBD 15            NOS 6

Data are presented as n/N, mean±SD, median (range). RCT -- randomized controlled trial; EVLP -- *ex vivo* lung perfusion; NEVLP -- non-EVLP; F -- Female; M -- Male; DBD -- donation after brain death; DCD -- donation after cardiac death; NA -- not available; SD -- standard deviation; NOS -- Newcastle-Ottawa Scale.

###### 

Characteristics of recipients.

  Author                                                  Sample size   Age (years)   Gender            Type of LTx         Indication for LTx   Follow-up                                                                                                                                                                                
  ------------------------------------------------------- ------------- ------------- ----------------- ------------------- -------------------- -------------- -------------------------- ----------------- ------------------------------------------------------- -------------------------------------------------------------------- -------------------
  Koch et al. \[[@b20-anntransplant-24-647]\]             11            41            55±7              55±6                F 13, M 8            F 17, M 24     BLT 7, SLT 1, Bilobar 1    BLT 41            IPF 2, COPD 8, CPFE 1                                   IPF 10, COPD 22, CPFE 3, CF 3, RLTx 1, Sarcoidosis 2                 Up to 500 days
  Warnecke et al. \[[@b16-anntransplant-24-647]\]         151           169           50.4± 13.1        50.0± 13.6          F 74, M 77           F 63, M 106    BLT 151                    BLT 169           COPD 46, PF 49, CF 31, IPH 13, Sarcoidosis 4, other 3   COPD 52, PF 57, CF 40, IPH 6, Sarcoidosis 8, other 6                 Up to 24 months
  Nilsson et al. \[[@b21-anntransplant-24-647]\]          54            271           52±12             51±13               NA                   NA             BLT 46, SLT 7, Bilobar 1   BLT 246, SLT 37   IPF 24, PAH 2, COPD 33, AAD 6, CF 20, other 15          IPF 25, PAH 6, COPD 28, AAD 13, CF 12, other 16                      Up to 5 years
  Zhang et al. \[[@b22-anntransplant-24-647]\]            9             18            53±13.3           50±9.5              F 5, M 4             F 10, M 8      BLT 9                      BLT 18            COPD 6, CF 2, PF 1                                      COPD 12, CF 4, PF 2                                                  Up to 36 months
  Slama et al. \[[@b17-anntransplant-24-647]\]            35            41            52.9 (21--68.3)   54.2 (19.7--66.7)   F 18, M 17           F 20, M 21     BLT 35                     BLT 41            Emphysema 14, PF 9, CF 7, other 5                       Emphysema 21, PF 7, CF 10, other 3                                   Up to 90 days
  Luc et al. \[[@b18-anntransplant-24-647]\]              7             4             52±18             58±4                F 4, M 3             F 1, M 3       NA                         NA                IPF 3, emphysema 2, CF 2                                IPF 2, emphysema 1, scleroderma 1                                    1 year
  Wallinder et al. 2016 \[[@b23-anntransplant-24-647]\]   27            145           55±13             52±14               NA                   NA             BLT 22, SLT 5              BLT 113, SLT 32   IPF 22, COPD 33, AAD 7, RLTx 4, CF 19, other 15         IPF 24, PAH 8, COPD 24, AAD 13, RLTx 9, CF 7, other 15               Up to 4 years
  Fisher et al. \[[@b24-anntransplant-24-647]\]           18            184           56 (20--64)       51 (18--70)         F 5, M 13            F 78, M 106    BLT 16, SLT 2              BLT 152, SLT 24   COPD 5, CF 4, ILD 7, NCFB 1, PAH 1                      COPD 40, CF 47, ILD 47, Emphysema 26, NCFB 8, OB 2, PAH 3, other 9   Up to 12 months
  Machuca et al. \[[@b19-anntransplant-24-647]\]          28            27            52±13             50±16               F 12, M 16           F 12, M 15     BLT 21, SLT 7              BLT 21, SLT 6     IPF 13, emphysema 8, CF 5, RLTx 1, Scleroderma 1        IPF 12, Emphysema 9, CF 4, RLTx 4, Scleroderma 1                     Up to 7 years
  Tikkanen et al. \[[@b25-anntransplant-24-647]\]         63            340           50.3± 14.6        52.3± 14.2          F 32, M 31           F 141, M 199   BLT 48, SLT 15             BLT 295, SLT 45   PF 22, COPD 20, CF 14, PAH 3, RLTx 1, other 3           PF 121, COPD 90, CF 67, PAH 14, RLTx 14, other 34                    Up to 5 years
  Fildes et al. \[[@b26-anntransplant-24-647]\]           9             46            3±9.4             49±12.0             F 4, M 5             F 24, M 222    NA                         NA                COPD 6, CF 1, PAH 1, IPF 1                              COPD 24, Bronchiectasis 7, CF 9, PAH 3, IPF 3                        Up to 12 months
  Sanchez et al. \[[@b15-anntransplant-24-647]\]          42            42            NA                NA                  NA                   NA             NA                         NA                IPF 19, COPD 13, PPH 1, other 9                         IPF 13, COPD 15, PPH 3, other 11                                     Up to 1 year
  Sage et al. \[[@b29-anntransplant-24-647]\]             31            81            40 (21--60)       41 (17--65)         F 20, M 11           F 42, M 39     BLT 31                     BLT 81            CF 15, COPD 9, PF 3, other 4                            CF 40, COPD 16, PF 12, other 13                                      Up to 1 year
  Boffini et al. \[[@b28-anntransplant-24-647]\]          8             28            46.6±9.8          51.7±14.7           F 2, M 6             F 7, M 21      BLT 8                      BLT 16, SLT 12    PF 4                                                    PF 13                                                                30 days
  Valenza et al. \[[@b4-anntransplant-24-647]\]           7             28            38±15             49±14               NA                   NA             BLT 6, SLT 1               BLT 14, SLT 14    CF 4, other 3                                           CF 14, PF 11, other 7                                                Up to 800 days
  Wallinder et al. 2014 \[[@b29-anntransplant-24-647]\]   11            47            56 (19--61)       56 (21--70)         NA                   NA             BLT 8, SLT 3               BLT 33, SLT 14    PF 5, COPD 4, other 2                                   PF 14, PAH 2, COPD 13, AAD 6, RLTx 5, other 7                        3 months
  Cypel et al. \[[@b30-anntransplant-24-647]\]            50            253           Median 56         Median 56           NA                   NA             BLT 38, SLT 12             BLT 223, SLT 30   Emphysema 19, PF 14, CF 12, other 5                     PF or PAH 98                                                         Up to 3.5 years
  Zych et al. \[[@b31-anntransplant-24-647]\]             6             86            43.5± 15.1        NA                  F 2, M 4             NA             NA                         NA                CF 2, Emphysema 3, HSP 1                                NA                                                                   Median 297.5 days
  Aigner et al. \[[@b32-anntransplant-24-647]\]           9             119           58 (18--66)       46 (13--66)         F 3, M 6             F 61, M 58     BLT 9                      NA                IPF 4, COPD 3, CF 2                                     NA                                                                   Up to 16 months
  Lindstedt et al. \[[@b33-anntransplant-24-647]\]        6             15            54.5 (35--64)     41 (24--66)         F 3, M 3             F 9, M 6       BLT 6                      BLT 15            COPD 3, PF 1, CF 1, AAD 1                               COPD 5, CF 7, PF 1, emphysema 1, PAH 1                               NA

Data are presented as n/N, mean±SD, median (range). LTx -- lung transplantation; EVLP -- *ex vivo* lung perfusion; NEVLP -- non-EVLP; F -- Female; M -- Male; BLT -- bilateral lung transplantation; SLT -- single lung transplantation; IPF -- interstitial pulmonary fibrosis; COPD -- chronic obstructive pulmonary disease; CPFE -- combined pulmonary fibrosis and emphysema; PAH -- pulmonary artery hypertension; PF -- pulmonary fibrosis; CF -- cystic fibrosis; IPH -- idiopathic pulmonary hypertension; PAH -- pulmonary artery hypertension; AAD -- a1-antitrypsin deficiency; RLTx -- re-transplantation; ILD -- interstitial lung disease; OB -- obliterative bronchiolitis; NCFB -- non-CF bronchiectasis; HSP -- hypersensitivity pneumonitis; NA -- not available; SD -- standard deviation.

###### 

EVLP features and its efficacy of improving donor lungs.

  Author                                                  Reason for EVLP                      Technological type                               EVLP solution                                                                     EVLP duration (min)   PaO~2~/FiO~2~ 100% (mmHg)   Accepted/total (pair)     Conversion rate   
  ------------------------------------------------------- ------------------------------------ ------------------------------------------------ --------------------------------------------------------------------------------- --------------------- --------------------------- ------------------------- ----------------- -------
  Koch et al. \[[@b20-anntransplant-24-647]\]             Marginal donor                       Toronto                                          Steen solution with meropenem, dexamethasone and heparin                          240                   273±70                      401±35                    9/11              81.8%
  Warnecke et al. \[[@b16-anntransplant-24-647]\]         Random assignment (standard donor)   OCS                                              OCS/LPD solution with ABO-compatible erythrocyte                                  300                   438.5± 80.0                 455.5± 111.1              150/151           99.3%
  Nilsson et al. \[[@b21-anntransplant-24-647]\]          Marginal donor                       Lund                                             Steen solution mixed with red blood cells, heparin and meropenem                  200±94                229.52±90                   438.79±75                 49.5/61           81.0%
  Zhang et al. \[[@b22-anntransplant-24-647]\]            Marginal donor                       Toronto                                          Steen solution with cefuroxime, dexamethasone and heparin                         240 (IQR 84--100.8)   285.77± 99.76               NA                        9/10              90.0%
  Slama et al. \[[@b17-anntransplant-24-647]\]            Random assignment (standard donor)   Toronto                                          Steen solution with heparin, cefuroxime and methylprednisolone                    266 (245--329)        514 (290--626)              NA                        37/39             94.9%
  Luc et al. \[[@b18-anntransplant-24-647]\]              Marginal donor                       OCS                                              OCS solution                                                                      210±101               367±119                     500±83                    7/7               100%
  Wallinder et al. 2016 \[[@b23-anntransplant-24-647]\]   Marginal donor                       Lund                                             Steen Solution with red blood cells                                               208 (100--577)        217.52± 85.1                477.04 (288.77--594.05)   24.5/32           76.6%
  Fisher et al. \[[@b24-anntransplant-24-647]\]           Marginal donor                       Hybrid EVLP (combining Toronto and Lund); Lund   Hybrid: Steen solution; Lund: Steen solution with red cells                       NA                    299 (95--535)               381.5 (74--638)           18/53             34%
  Machuca et al. \[[@b19-anntransplant-24-647]\]          Marginal donor                       Toronto                                          Steen solution with heparin, methylprednisolone and imipenem/cilastatin           240--360              380±103                     NA                        28/35             80%
  Tikkanen et al. \[[@b25-anntransplant-24-647]\]         Marginal donor                       Toronto                                          Steen solution                                                                    175 (73--383)         332.5± 127.0                346.1± 104.0              63/73             86%
  Fildes et al. \[[@b26-anntransplant-24-647]\]           Marginal donor                       Lund                                             Steen solution with blood cells, trometamol and antibiotic                        240                   \<300                       \>300                     9/9               100%
  Sanchez et al. \[[@b15-anntransplant-24-647]\]          Marginal donor                       Toronto                                          Steen solution                                                                    180--360              NA                          NA                        42/76             55%
  Sage et al. \[[@b29-anntransplant-24-647]\]             Marginal donor                       Toronto                                          Steen solution                                                                    243 (124--460)        274 (162--404)              511 (378--668)            31/32             96.6%
  Boffini et al. \[[@b28-anntransplant-24-647]\]          Marginal donor                       Toronto                                          Steen solution with antibiotics, heparin and methylprednisolone                   282.8± 57.1           200±85                      438±8                     8/11              73.0%
  Valenza et al. \[[@b4-anntransplant-24-647]\]           Marginal donor                       Lund                                             Steen solution with red blood cells, methylprednisolone, cefazolin, and heparin   268±104               264±78                      518±55                    7/8               87.5%
  Wallinder et al. 2014 \[[@b29-anntransplant-24-647]\]   Marginal donor                       Lund                                             Steen Solution with red blood cells                                               191 (156--577)        209.27 (68.26--313.53)      447.04 (303.02--572.3)    10/11             90.9%
  Cypel et al. \[[@b30-anntransplant-24-647]\]            Marginal donor                       Toronto                                          Steen solution with methylprednisolone, imipenem/cilastatin, and heparin          240--360              334 (143--532)              Median 513                50/58             86.2%
  Zych et al. \[[@b31-anntransplant-24-647]\]             Marginal donor                       Toronto                                          Steen Solution with heparin, methylprednisolone, and antibiotics                  141±28.83             317.73±105.98               429.94± 68.26             6/13              46.2%
  Aigner et al. \[[@b32-anntransplant-24-647]\]           Marginal donor                       Toronto                                          Steen solution                                                                    199 (171--290)        216 (133--271)              466 (434--525)            9/13              69.2%
  Lindstedt et al. \[[@b33-anntransplant-24-647]\]        Marginal donor                       Lund                                             Steen solution with ABO-compatible erythrocyte, imipenem, insulin, and heparin    89 (66--121)          158.26 (86.26--215.27)      515.29 (387.03--596.3)    6/8               75.0%

Data are presented as n/N, mean±SD, median (range) or median (IQR). NA -- not available; SD -- standard deviation; IQR -- inter-quartile range.
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